A recently published study from the University of Freiburg in Germany has found that rolling a joint is enough to fail a drug test. Even indirect contact with cannabis can give you a false positive, with big implications for legal cases that revolve around a drug test as evidence.

Researchers chose 10 lucky participants to roll one joint on five consecutive days, and urine tested them to make sure they didn’t smoke before or during the study. By the fifth day, and the fifth joint, most of the participants had detectable levels of THC and THCA in their hair. Even four weeks after their first exposure hair tests still showed both THCA and decarboxylated THC.

Those who have had to submit to drug tests know all too well about THC’s habit of lingering in the body for long periods of time. This study proves you don’t even need to get high to show up positive; the act of breaking up bud exposes your skin to enough THC to show up on a drug test.

The California Senate approved AB 258, the Medical Cannabis Organ Transplant Act, earlier today by a margin of 31-1. AB 258 prohibits discrimination against medical cannabis patients in the organ transplant process, unless a doctor has determined that medical cannabis use is clinically significant to the transplant process. Medical cannabis patients in California are routinely removed from the organ transplant waiting list if they test positive for cannabis use – even legal doctor-recommended medical cannabis. AB 258 was authored by Assemblymember Marc Levine (D-San Rafael) and sponsored by Americans for Safe Access (ASA).

“AB 258 is about fundamental fairness and compassion. Legal medical cannabis patients should never face a choice between their doctor-recommended medicine and a life-saving organ transplant,” said Don Duncan ASA’s California Director. “AB 258 will help the law catch up with science, which has shown that medical cannabis patients are just as likely to benefit from an organ transplant as other patients.”

On June 15th over 200 patients and advocates participated in the ASA California Citizen Lobby Day, which focused on educating lawmakers about AB 258 and other medical cannabis legislation. During the lobby day ASA began a postcard campaign to encourage Governor Jerry Brown to support AB 258.

An analysis of 75 edible marijuana products sold to patients in Seattle, San Francisco and Los Angeles found that labels on just 17 percent accurately described their levels of THC, the main psychoactive ingredient, researchers reported Tuesday.

Sixty percent of the products had less THC than their packages advertised, and 23 percent of them had more THC than claimed.

“We need a more accurate picture of what’s being offered to patients,” said Dr. Donald Abrams, the chief of hematology and oncology at San Francisco General Hospital. He was not involved in the new study, which was published in JAMA.

“What we have now in this country is an unregulated medical marijuana industry, due to conflicts between state and federal laws,” Dr. Abrams said.

After ingesting marijuana, patients experience the maximal high one to three hours later. (It is felt within minutes after smoking.) Inaccurate labels complicate the consumption of marijuana for medical purposes.